Abstract:Objective Major depression disorder (MDD) is a harmful disorder, and the pathological mechanism remains unclear. The primary pharmacotherapy regimen for MDD is selective serotonin reuptake inhibitors (SSRIs), but fewer than 40% of patients with MDD are in remission following initial treatment. Neuroimaging biomarkers of treatment efficacy can be used to guide personalized treatment in MDD. This study aims to determine if cortical thickness can be used as a predictor for SSRIs. Methods A total of 126 first-episode, drug-naive MDD patients (MDDs) and 71 healthy controls (HCs) were enrolled in our study. Demographic data were collected according to the self-made case report form (CRF) at the baseline of all subjects. Magnetic resonance imaging (MRI) scanning was performed for all the participants at baseline, and all imaging was processed using the DPABISurf software. All MDDs were treated with SSRIs, and symptoms were assessed at both the baseline and 2 weeks using the 17-item Hamilton Rating Scale (HAMD-17). According to HAMD-17 total score improvement from baseline to the end of 2 weeks, the MDDs were divided into the non-responder group (defined as ≤ 20% HAMD-17 reduction) and responder group (defined as ≥50% HAMD-17 reduction). The receiver operating characteristic (ROC) curve was used to analyze the diagnostic value of MDDs' and HCs' cortical thickness for MDD. Correlation analysis was performed for the responder group and the non-responder group separately to identify the relationship between cortical thickness and SSRI treatment efficacy. To analyze whether cortical thickness was sufficient to differentiate responders and non-responders at baseline, we used ROC curve analysis. Results Significant decreases were found in the cortical thickness of the right supplementary motor area (SMA) in MDDs at the baseline (corrected by the Monte Carlo permutation correction, cluster-wise significant threshold at p < 0.025 and vertex-wise threshold at p = 0.001), area under the curve (AUC) = 0.732 [95% confidence interval (CI) = 0.233–0.399]. In the responder group, the cortical thickness of the right SMA was significantly thinner than in the non-responder group at baseline. There was a negative correlation ( r = −0.373, p = 0.044) between the cortical thickness of SMA (0 weeks) and HAMD-17 reductive rate (2 weeks) in the responder group. The results of ROC curve analyses of the responder and non-responder groups were AUC = 0.885 (95% CI = 0.803–0.968), sensitivity = 73.5%, and specificity = 96.6%, and the cutoff value was 0.701. Conclusion Lower cortical thickness of the right SMA in MDD patients at the baseline may be a neuroimaging biomarker for MDD diagnosis, and a greater extent of thinner cortical thickness in the right SMA at baseline may predict improved SSRI treatment response. Our study shows the potential of cortical thickness as a possible biomarker that predicts a patient's clinical treatment response to SSRIs in MDD.

Measures of Connectivity and Dorsolateral Prefrontal Cortex Volumes and Depressive Symptoms Following Treatment With Selective Serotonin Reuptake Inhibitors in Adolescents

Resting-state functional connectivity of the amygdala and longitudinal changes in depression severity in adolescent depression

Resting-State fMRI in Predicting Response to Treatment With SSRIs in First-Episode, Drug-Naive Patients With Major Depressive Disorder

Case-control Resting-State Fmri Study of Brain Functioning among Adolescents with First-Episode Major Depressive Disorder

Disrupted Intrinsic Functional Connectivity of the Cognitive Control Network Underlies Disease Severity and Executive Dysfunction in First-Episode, Treatment-Naive Adolescent Depression.

Acute Neurofunctional Effects of Escitalopram in Pediatric Anxiety: A Double-Blind, Placebo-Controlled Trial

Effects of rTMS Intervention on Functional Neuroimaging Activities in Adolescents with Major Depressive Disorder Measured Using Resting-State fMRI

Resting state functional connectivity patterns as biomarkers of treatment response to escitalopram in patients with major depressive disorder

The effects of antidepressant treatment on resting-state functional brain networks in patients with major depressive disorder.

Longitudinal amygdala resting state functional connectivity develops differently in adolescents with internalising disorders compared to healthy peers

Cortical Thickness Predicts Response Following 2 Weeks of SSRI Regimen in First-Episode, Drug-Naive Major Depressive Disorder: An MRI Study

Changes in P300 amplitude to negative emotional stimuli correlate with treatment responsiveness to sertraline in adolescents with depression

Effects of 12‐week escitalopram treatment on resting‐state functional connectivity of large‐scale brain networks in major depressive disorder

Differential Effects of Antidepressant Treatment on Long-Range and Short-Range Functional Connectivity Strength in Patients with Major Depressive Disorder

Case-control resitng-state fMRI study of brain funcitoning among adolescents with ifrst-episode major depressive disorder

Predicting Responses to Electroconvulsive Therapy in Adolescents with Treatment-Refractory Depression Based on Resting-State fMRI

Striatal Functional Connectivity Alterations after Two-Week Antidepressant Treatment Associated to Enduring Clinical Improvement in Major Depressive Disorder

Short-term Effects of Escitalopram on Regional Brain Function in First-Episode Drug-Naive Patients with Major Depressive Disorder Assessed by Resting-State Functional Magnetic Resonance Imaging

Acute Neurofunctional Effects of Escitalopram During Emotional Processing in Pediatric Anxiety: a Double-Blind, Placebo-Controlled Trial

Eight-week Antidepressant Treatment Changes Intrinsic Functional Brain Topology in First-Episode Drug-Naïve Patients with Major Depressive Disorder

Alteration of Whole Brain ALFF/fALFF and Degree Centrality in Adolescents With Depression and Suicidal Ideation After Electroconvulsive Therapy: A Resting-State fMRI Study